Towards Personalized Management of Ovarian Cancer.
Mashael AlgethamiSanat KulkarniMaaz T SadiqHiu K C TangJuliette BrownlieJennie N JeyapalanNigel P MonganEmad A RakhaSrinivasan MadhusudanPublished in: Cancer management and research (2022)
Despite advances in surgery and chemotherapy, the overall outcomes for patients with advanced ovarian cancer remain poor. Although initial response rates to platinum-based chemotherapy is about 60-80%, most patients will have recurrence and succumb to the disease. However, a DNA repair-directed precision medicine strategy has recently generated real hope in improving survival. The clinical development of PARP inhibitors has transformed lives for many patients with BRCA germline-deficient and/or platinum-sensitive epithelial ovarian cancers. Antiangiogenic agents and intraperitoneal chemotherapy approaches may also improve outcomes in patients. Moreover, evolving immunotherapeutic opportunities could also positively impact patient outcomes. Here we review the current clinical state of PARP inhibitors and other clinically viable targeted approaches in ovarian cancer.
Keyphrases
- dna repair
- end stage renal disease
- dna damage
- ejection fraction
- chronic kidney disease
- newly diagnosed
- peritoneal dialysis
- prognostic factors
- minimally invasive
- patient reported outcomes
- radiation therapy
- squamous cell carcinoma
- drug delivery
- acute coronary syndrome
- insulin resistance
- percutaneous coronary intervention
- weight loss